V-Square Quantitative Management’s Genmab GMAB Stock Holding History

V-Square Quantitative Management’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36K	Buy	1,309 +42	+3%	+$1.12K	﹤0.01%	628
2026 Q1	$34K	Buy	+1,267	New	+$38K	﹤0.01%	632

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

V-Square Quantitative Management's GMAB Position: Q2 2026 in Review

V-Square Quantitative Management increased its Genmab (GMAB) stake by 3.3% in Q2 2026, buying an estimated $1.12K and bringing the position to 1,309 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #628.

V-Square Quantitative Management first reported a position in GMAB in Q1 2026 and has held it in 2 quarters since. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

V-Square Quantitative Management held 1,309 shares of Genmab worth $36K as of Q2 2026.
V-Square Quantitative Management bought 42 Genmab shares in Q2 2026, an estimated $1.12K.
Genmab made up ﹤0.01% of V-Square Quantitative Management's portfolio in Q2 2026, its #628 holding.
V-Square Quantitative Management first reported a position in Genmab in Q1 2026 and has held it in 2 quarters since.
290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on V-Square Quantitative Management's 13F filing for Q2 2026, filed 27 Jul 2026.